Information on these pages is being updated and will be move to the Australian Immunisation Handbook shortly.
| Date | Update | Page |
|---|---|---|
| 2 June 2023 | Removed information on use of Moderna 6 months to 5 years formulation (blue cap/purple stripe), as this is no longer available in Australia. Added updates to primary course recommendations and co-administration in children. | Recommendations, Vaccines, dosage and administration, Transporting storing and handling |
| 20 March 2023 | Added recommendations and information on Moderna bivalent original/Omicron BA.4/5. Removed information about AstraZeneca (apart from safety information) as it is no longer available in Australia. | All pages |
| 17 February 2023 |
Clinical guidance updated to:
|
All pages |
| 16 December 2022 | Information updated regarding transport, storage and handling of vaccines | Transporting storing and handling |
| 9 December 2022 | Recommendations and information on Comirnaty (Pfizer) vaccine for children aged 6 months to 4 years have been updated |
Recommendations, Vaccines, dosage and administration, Adverse events, Vaccine information |
| 28 November 2022 | Recommendations and information on Comirnaty (Pfizer) Bivalent Original/Omicron BA.1 (Pfizer bivalent) |
Recommendations, Vaccines, dosage and administration, Adverse events, Vaccine information |
| 24 October 2022 | Recommendations and information on Comirnaty (Pfizer) vaccine as a booster dose for children aged 5 to 11 years |
Recommendations, Vaccines, dosage and administration, Adverse events, Vaccine information |
| 5 October 2022 | Recommendations and information on Spikevax (Moderna) Bivalent Original/Omicron BA.1 (Moderna bivalent) vaccine have been updated |
Recommendations, Vaccines, dosage and administration, Contraindications and precautions, Adverse events, Clinical features of COVID-19 disease, Vaccine information Transporting storing and handling |
| 23 September 2022 | Latest information on myocarditis and pericarditis after COVID-19 vaccines | COVID-19 vaccines and cardiac inflammation |
| 21 September 2022 | Precautions for Spikevax (Moderna) have been updated to include capillary leak syndrome | Contraindications and precautions |
| 31 August 2022 | Recommendations and information on Spikevax (Moderna) vaccine for children aged 6 months to under 5 years have been updated |
Recommendations, Vaccines, dosage and administration, Adverse events, Vaccine information, Transporting storing and handling |
| 31 August 2022 | Recommendations and information on Nuvaxovid (Novavax) vaccine for adolescents aged 12 to 17 years have been updated |
Recommendations, Vaccines, dosage and administration, Adverse events, Vaccine information |
| 31 August 2022 | Table of medical conditions of increased risk of severe COVID-19 has been updated | Clinical features of COVID-19 disease |
|
7 July 2022 |
Updated recommendations for a winter dose of COVID-19 vaccine |
|
|
1 July 2022 |
Recommendations on the use of Nuvaxovid (Novavax) boosters in people 18 years and older have been updated |
|
|
15 June 2022 |
Recommendations for boosters in high-risk adolescents aged 12-15 years have been included |
|
|
29 April 2022 |
The recommended interval between SARS-CoV-2 infection and vaccination has been updated |
|
|
29 April 2022 |
Recommendations on vaccination after treatment with anti-SARS-CoV-2 monoclonal antibodies have been updated |
|
|
29 April 2022 |
The recommended dosing schedule for Comirnaty (Pfizer) and Spikevax (Moderna) has been updated |
Recommendations – recommended and variations on vaccine schedule |
|
25 March 2022 |
Recommendations and evidence on the use of an additional booster dose have been included |
Recommendations – Booster dose recommendations, Vaccine information, Also see: ATAGI recommendations on the use of an additional winter booster dose |
|
2 March 2022 |
Recommendations on the use of Nuvaxovid (Novavax) as a booster |
|
|
28 February 2022 |
Recommendations on the use of Spikevax (Moderna) have been included |
Recommendations, Vaccine doses and administration, Adverse events, Vaccine information |
|
23 February 2022 |
Recommendations on the use of Comirnaty (Pfizer) in adolescents aged 16 to 17 years have been included |
|
|
23 February 2022 |
Information on the use of Nuvaxovid – the Novavax COVID-19 vaccine has been incorporated |
Recommendations, Vaccine doses and administration, Contraindications and precautions, Adverse events |
|
23 February 2022 |
Recommendations on the timing of booster doses following the primary course have been updated from 4 months to 3 months |
|
|
24 January 2022 |
The time allowable for temporary deferral of vaccination following SARS-CoV-2 infection reduced from 6 month to 4 months |
|
|
17 January 2022 |
Severely immunocompromised children aged 5 – 11 years are recommended to receive a third primary dose of COVID-19 vaccine, in line with severely immunocompromised individuals aged 12 years and over. |